Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-ranging study of QLC7401 in primary hypercholesterolemia or mixed dyslipidemia with inadequately controlled LDL-C despite optimized lipid-lowering therapy
CTR20244751Phase 2Completed
- Sponsor
- Suzhou Ribo Life Science Co., Ltd.
- Start
- Jan 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of rbd7022 in hypercholesterolemia, combined dyslipidaemia, sponsored by Suzhou Ribo Life Science Co., Ltd.. Started Jan 2025; status: completed.
02
Drugs
rbd7022
03
Conditions
hypercholesterolemiacombined dyslipidaemia
Beyond the preview
Go deeper on CTR20244751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244751.